TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06469944: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcin

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT06469944 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06469944 Rescue Dossier →